Role of renin-angiotensin system in adipose tissue dysfunction

被引:32
作者
Iwai, Masaru [1 ]
Horiuchi, Masatsugu [1 ]
机构
[1] Ehime Univ, Dept Mol Cardiovasc Biol & Pharmacol, Grad Sch Med, Tohon, Ehime 7910295, Japan
关键词
adipocyte; angiotensin; differentiation; insulin resistance; receptor; ACTIVATED-RECEPTOR-GAMMA; INSULIN SENSITIVITY; ADIPOCYTE DIFFERENTIATION; TYPE-2; BLOCKADE; MICE; RESISTANCE; OBESITY; FAT; ADIPONECTIN;
D O I
10.1038/hr.2009.55
中图分类号
R6 [外科学];
学科分类号
100210 [外科学];
摘要
Blockade of angiotensin II type 1 (AT(1)) receptor improves insulin sensitivity and diabetic condition. In short-term regulation, angiotensin II changes lipid metabolism and in long-term regulation, it affects insulin sensitivity and adipocyte differentiation in adipose tissue. These effects are mainly mediated by AT(1) receptor. AT(1) receptor blocker improves insulin sensitivity and induces adipocyte differentiation by increasing peroxisome proliferator-activated receptor-gamma (PPAR gamma) and transcription factors in adipose tissue in diabetic and atherosclerotic models. Clinical studies indicate that AT(1) receptor blockers prevent the new onset of diabetes and improve insulin sensitivity. On the other hand, AT(2) receptor stimulation appears to cause antagonistic actions against AT(1) receptor signaling. Although further investigations are necessary on the AT(2) receptor function in adipose tissue, studies using AT(2) receptor agonists, in addition to those using AT(1) receptor blockers, would contribute to the treatment of metabolic syndrome and associated pathological disorders. Hypertension Research (2009) 32, 425-427; doi: 10.1038/hr.2009.55; published online 1 May 2009
引用
收藏
页码:425 / 427
页数:3
相关论文
共 29 条
[1]
Adipose tissue as an endocrine organ [J].
Ahima, Rexford S. .
OBESITY, 2006, 14 :242-249
[2]
Sympathetic modulation by carvedilol and losartan reduces angiotensin II-mediated lipolysis in subcutaneous and visceral fat [J].
Cabassi, A ;
Coghi, P ;
Govoni, P ;
Barouhiel, E ;
Speroni, E ;
Cavazzini, S ;
Cantoni, AM ;
Scandroglio, R ;
Fiaccadori, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (05) :2888-2897
[3]
Angiotensin II-mediated development of vascular diseases [J].
Daugherty, A ;
Cassis, L .
TRENDS IN CARDIOVASCULAR MEDICINE, 2004, 14 (03) :117-120
[4]
The cardiovascular continuum and renin-angiotensin-aldosterone system blockade [J].
Dzau, V .
JOURNAL OF HYPERTENSION, 2005, 23 :S9-S17
[6]
Incident diabetes in clinical trials of anti hypertensive drugs: a network meta-analysis [J].
Elliott, William J. ;
Meyer, Peter M. .
LANCET, 2007, 369 (9557) :201-207
[7]
Furuhashi M, 2004, J HYPERTENS, V22, P1977, DOI 10.1097/00004872-200410000-00021
[8]
Angiotensin II: a major regulator of subcutaneous adipose tissue blood flow in humans [J].
Goossens, GH ;
McQuaid, SE ;
Dennis, AL ;
van Baak, MA ;
Blaak, EE ;
Frayn, KN ;
Saris, WHM ;
Karpe, F .
JOURNAL OF PHYSIOLOGY-LONDON, 2006, 571 (02) :451-460
[9]
Improvement of insulin sensitivity by antagonism of the renin-angiotensin system [J].
Henriksen, Erik J. .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2007, 293 (03) :R974-R980
[10]
IWAI M, 2009, AM J HYPERT IN PRESS